重组人白介素11治疗慢性特发性血小板减少性紫癜26例观察

慢性特发性血小板减少性紫癜（chronic idiopathic thrombocytopenic purpura，CITP）一般采用激素治疗，必要时还需给予免疫抑制剂治疗，为了解重组人白介素11（rhIL-11）对慢性特发性血小板减少性紫癜的疗效，本研究将26例血小板数〈60．00×10^9／L的CITP患者分为两组，对照组采用传统的激素与免疫抑制治疗，rhIL—11组在传统治疗的基础上给予rhIL—1125μg／（k·d），每日1次，皮下注射，14天为1个疗程，共治疗2个疗程，观察疗效。结果表明：23例CITP患者治疗后血小板减少情况均得到不同程度好转，只有3例治疗后血小板减少情况没有改善。对照组和rhIL—11组的血小板计数分别由治疗前的26．15×10^9／L和27．84×10^9／L增加为66．62×10^9／L和105．62×10^9／L，rhIL—11组治疗后血小板计数明显高于对照组（P〈0．05），临床出血症状减轻，在rhIL-11组中8例患者的血小板恢复正常（〉100×10^9／L），获得满意治疗效果。结论：rhIL-11联合传统的激素治疗对慢性ITP患者血小板减少有较好的治疗效果。

Curative Effect of rhIL-11 on 26 Patients with Chromic Idiopathic Thrombocytopenic Purpura

Traditional treatment of chronic idiopathic thrombocytopenic purpura (CITP) is usually adopted as hormonal therapy. If necessary, it also can be given immunosuppressive therapy. In order to investigate the curative effect of rhIL-11 on patients with ITP, 26 patients were divided into control group and rhIL-11 group, each group with 13 patients. Control group was given traditional hormonal therapy and immunosuppressive therapy, while rhIL-11 group was given rhIL-11 on base of tradional therapy. rhIL-11 25 microg/(kg.d) was injected s.c. for 28 days. The results showed that 23 out of 26 patients obtained obviously curative effect in platelet count, especially in rhIL-11 group, but another 3 patients had no response on therapy. The platelet counts of control and rhIL-11 groups increased from 26.15 x 10(9)/L and 27.84 x 10(9)/L before treatment to 66.62 x 10(9)/L and 105.62 x 10(9)/L after treatment. The platelet count of rhIL-11 group after treatment was remarkably higher than that of the control group (p < 0.05). Platelet count of 8 patients in rhIL-11 group recovered to normal. It is concluded that rhIL-11 combined with traditional hormone-immuno-suppressive therapy is effective to CITP.